Research programme: gene therapeutics - Bayer HealthCare/Broad Institute/Harvard UniversityAlternative Names: cancer therapeutics - Bayer HealthCare/Broad Institute; cardiovascular disorder therapeutics - Bayer Healthcare/Broad Institute/Harvard University
Latest Information Update: 22 Apr 2015
At a glance
- Originator Bayer HealthCare; Broad Institute; Harvard University
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Cardiovascular disorders
Most Recent Events
- 31 Mar 2015 Early research in Cardiovascular disorders in USA (unspecified route)
- 10 Sep 2013 Early research in Cancer in USA (unspecified route)